Combination of 5-aminosalicylic acid and hyperthermia synergistically enhances apoptotic cell death in HSC-3 cells due to intracellular nitric oxide/peroxynitrite generation. (1st June 2019)
- Record Type:
- Journal Article
- Title:
- Combination of 5-aminosalicylic acid and hyperthermia synergistically enhances apoptotic cell death in HSC-3 cells due to intracellular nitric oxide/peroxynitrite generation. (1st June 2019)
- Main Title:
- Combination of 5-aminosalicylic acid and hyperthermia synergistically enhances apoptotic cell death in HSC-3 cells due to intracellular nitric oxide/peroxynitrite generation
- Authors:
- Moniruzzaman, Rohan
Rehman, Mati Ur
Zhao, Qing-Li
Jawaid, Paras
Mitsuhashi, Yohei
Sakurai, Kotaro
Heshiki, Wataru
Ogawa, Ryohei
Tomihara, Kei
Saitoh, Jun-ichi
Noguchi, Kyo
Kondo, Takashi
Noguchi, Makoto - Abstract:
- Abstract: The repurposing of existing FDA-approved non-cancer drugs is a potential source of new treatment options for cancer patients. An anti-inflammatory drug, 5-aminosalicylic acid (5-ASA), has been clinically used to treat inflammatory bowel disease. Hyperthermia (HT) is widely applicable addendum therapy with the existing cancer treatment modalities. Here, we addressed how 5-ASA combined with HT induces lethal effects in human oral squamous cell carcinoma (OSCC) HSC-3 cells. We found that 5-ASA/HT combination significantly inhibited the viability of HSC-3 cells, while cytotoxic effects in primary human dermal fibroblast cells were minor. Apoptotic endpoints were significantly increased by the 5-ASA/HT combined treatment, as evidenced by presence of Annexin V-FITC/PI positive cells, loss of MMP, Bcl-2/Bax ratio alteration, and increased Fas, cleaved Bid, and caspase expression. Interestingly, the enhancement of apoptosis was reversed in the presence of ON/ONOO − scavengers. These findings indicate that the combination treatment enhances apoptosis via ON/ONOO − mediated ER stress-Ca 2+ -mitochondria signaling and caspase-dependent apoptotic pathways. Our findings provide novel evidence that the combination of 5-ASA and HT is a promising approach for the enhancement of apoptosis; it may serve as an effective strategy for treating human OSCC. Highlights: Anti-inflammatory agent 5-ASA is a potent thermo-sensitizer. 5-ASA with HT enhances intracellular NO generation andAbstract: The repurposing of existing FDA-approved non-cancer drugs is a potential source of new treatment options for cancer patients. An anti-inflammatory drug, 5-aminosalicylic acid (5-ASA), has been clinically used to treat inflammatory bowel disease. Hyperthermia (HT) is widely applicable addendum therapy with the existing cancer treatment modalities. Here, we addressed how 5-ASA combined with HT induces lethal effects in human oral squamous cell carcinoma (OSCC) HSC-3 cells. We found that 5-ASA/HT combination significantly inhibited the viability of HSC-3 cells, while cytotoxic effects in primary human dermal fibroblast cells were minor. Apoptotic endpoints were significantly increased by the 5-ASA/HT combined treatment, as evidenced by presence of Annexin V-FITC/PI positive cells, loss of MMP, Bcl-2/Bax ratio alteration, and increased Fas, cleaved Bid, and caspase expression. Interestingly, the enhancement of apoptosis was reversed in the presence of ON/ONOO − scavengers. These findings indicate that the combination treatment enhances apoptosis via ON/ONOO − mediated ER stress-Ca 2+ -mitochondria signaling and caspase-dependent apoptotic pathways. Our findings provide novel evidence that the combination of 5-ASA and HT is a promising approach for the enhancement of apoptosis; it may serve as an effective strategy for treating human OSCC. Highlights: Anti-inflammatory agent 5-ASA is a potent thermo-sensitizer. 5-ASA with HT enhances intracellular NO generation and subsequent reacts with . O2 − to form ONOO − . 5-ASA/HT co-treatment enhances apoptosis via intrinsic and extrinsic apoptotic pathway. ER stress-Ca 2+ mediated pathway also contribute to the enhancement of apoptosis. The combination of 5-ASA with HT might be a potential therapeutic strategy for OSCC. … (more)
- Is Part Of:
- Cancer letters. Volume 451(2019)
- Journal:
- Cancer letters
- Issue:
- Volume 451(2019)
- Issue Display:
- Volume 451, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 451
- Issue:
- 2019
- Issue Sort Value:
- 2019-0451-2019-0000
- Page Start:
- 58
- Page End:
- 67
- Publication Date:
- 2019-06-01
- Subjects:
- Cancer cell death -- Reactive oxygen and nitrogen species -- Drug repurposing -- OSCC
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2019.03.004 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9731.xml